Cytokinetics is expected to report a Q3 2026 loss of $1.46 per share on revenue of $41.20 million, with the current $62.99 stock price trading well below the $108.44 analyst consensus.
Investors are laser-focused on the commercial trajectory of MYQORZO (aficamten), particularly its net product revenue following recent global approvals in the U.S. and Europe.
The report will be scrutinized for updates on the supplemental NDA submission for non-obstructive HCM planned for Q4 2026 and the upcoming November 14 PDUFA date for the MAPLE-HCM indication. Management is also expected to provide clarity on its $1.7 billion cash position as it transitions into a fully integrated commercial biopharmaceutical organization.